-+ 0.00%
-+ 0.00%
-+ 0.00%

Zhifei Biology (300122.SZ): Application for clinical trial of freeze-dried recombinant respiratory syncytial virus protein vaccine (CHO cells) accepted

Zhitongcaijing·11/17/2026 09:17:18
Listen to the news

Zhitong Finance App News, Zhifei Biotech (300122.SZ) issued an announcement. The company recently learned that the freeze-dried recombinant respiratory syncytial virus protein vaccine (CHO cells) (“freeze-dried recombinant RSV vaccine” for short) developed by the wholly-owned subsidiary Anhui Zhifeilong Koma Biopharmaceutical Co., Ltd. (“Zhifeilong Koma”) has obtained a notice of acceptance of the drug clinical trial application from the State Drug Administration. If no negative or questioning opinions have been received from the Drug Review Center within 60 days from the date of acceptance, Zhifeilong Koma may conduct clinical trials according to the submitted plan.

According to reports, Zhifeilong Koma has developed a recombinant protein RSV vaccine using genetically-engineered recombinant technology. Its active ingredient is recombinant RSV fusion pre-F protein expressed by CHO cells, and is complemented by a novel adjuvant developed independently. Preclinical data shows that this product is safe and can induce RSV-specific protective immune responses in mice, cotton mice, rhesus monkeys, etc., and is suitable for preventing RSV-induced lower respiratory infections in adults.